Lv2
140 积分 2023-10-20 加入
Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges
25天前
已完结
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial
28天前
已完结
Epidemiology and environmental aspects of marginal zone lymphomas
29天前
已完结
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
1个月前
已完结
Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma
1个月前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
1个月前
已完结
Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
1个月前
已完结
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
1个月前
已完结
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma∗
2个月前
已完结
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
2个月前
已完结
皖公网安备34019202002308
